Drug Trial Radar · NCT07592273
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
576
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jun 2028
Study completion Jan 2036
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (SCS) for the treatment of diabetic retinopathy (DR) and prevention of vision-threatening events (VTEs) in participants with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME). This study will consist of 3 portions: a Phase 2b portion, a Phase 3 portion, and a bilateral treatment portion. Approximately 576 adult participants will be enrolled in the study across multiple sites in the United States and Puerto Rico. In the Phase 2b and Phase 3 portions, participants will be randomized to different groups to receive sura-vec and prophylactic steroids or sham and artificial tears in their study eye. If assigned to sham, participants will be given an opportunity to cross over and receive treatment with sura-vec. In the bilateral treatment portion, participants will be enrolled to receive sura-vec and prophylactic steroids in both eyes. In all 3 portions, follow-up in the study will continue through 5 years following administration of sura-vec in each eye. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Diabetic Retinopathy
Interventions
Surabgene LomparvovecDrug
Solution Injection
ShamDrug
needleless injection without fluid
Topical SteroidDrug
Topical Drops
Artificial TearsDrug
Topical Drops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study EyeTime frame: At Week 52
- Phase 3: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study EyeTime frame: At Week 52
- Bilateral Portion: Bilateral portion: Number of participants experiencing ocular Adverse Events (AEs), Serious Adverse Events (SAEs), or any Adverse Events of Special Interest (AESIs)Time frame: Up to Approximately Week 104
- Bilateral Portion: Participants Who Experience Intraocular InflammationTime frame: Up to Approximately Week 104
- Bilateral Portion: Participants Who Experience Scleral Inflammation Including EpiscleritisTime frame: Up to Approximately Week 104
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center - Mesa /ID# 283000
Mesa, Arizona · Recruiting
Retinal Consultants Of Arizona - Phoenix - North /ID# 283407
Phoenix, Arizona · Recruiting
Retina Macula Institute of Arizona /ID# 282881
Scottsdale, Arizona · Recruiting
California Retina Consultants - Bakersfield /ID# 282990
Bakersfield, California · Recruiting
Retina-Vitreous Associates Medical Group - Beverly Hills /ID# 282995
Beverly Hills, California · Recruiting
Retinal Diagnostic Center /ID# 275055
Campbell, California · Recruiting
The Retina Partners /ID# 274741
Encino, California · Recruiting
Northern California Retina Vitreous Associates /ID# 282994
Mountain View, California · Recruiting
California Eye Specialists Medical Group /ID# 274705
Pasadena, California · Recruiting
Retina Consultants San Diego /ID# 274748
Poway, California · Recruiting
Retinal Consultants - Sacramento - Greenback Lane /ID# 283018
Sacramento, California · Recruiting
West Coast Retinal Medical Group /ID# 283007
San Francisco, California · Recruiting
California Retina Consultants - Santa Barbara /ID# 283050
Santa Barbara, California · Recruiting
Macula Retina Vitreous Center - Torrance /ID# 282878
Torrance, California · Recruiting
Bay Area Retina Associates /ID# 275032
Walnut Creek, California · Recruiting
Southwest Retina Research Center /ID# 276094
Durango, Colorado · Recruiting
Colorado Retina Associates /ID# 283006
Lakewood, Colorado · Recruiting
Advanced Vision Surgery Center /ID# 275017
Longmont, Colorado · Recruiting
Florida Retina Consultants - Lakeland /ID# 275012
Lakeland, Florida · Recruiting
Florida Retina Institute - Orlando /ID# 283034
Orlando, Florida · Recruiting
Retina Speciality Institute /ID# 274996
Pensacola, Florida · Recruiting
Southeast Retina Center /ID# 274739
Augusta, Georgia · Recruiting
Illinois Retina Associates S.C /ID# 283048
Chicago, Illinois · Recruiting
University Retina - Lemont /ID# 283021
Lemont, Illinois · Recruiting
Springfield Clinic - First /ID# 283028
Springfield, Illinois · Recruiting
Retina Associates - Lenexa /ID# 283004
Lenexa, Kansas · Recruiting
Maine Eye Center - Marginal Way Campus /ID# 275039
Portland, Maine · Recruiting
Mid Atlantic Retina Specialists - Hagerstown /ID# 274725
Hagerstown, Maryland · Recruiting
Sierra Eye Associates /ID# 274737
Reno, Nevada · Recruiting
Retina Center Of New Jersey /ID# 283088
Bloomfield, New Jersey · Recruiting
Retina Associates Of Cleveland - Middleburg Heights Office /ID# 275985
Middleburg Heights, Ohio · Recruiting
Retina Northwest /ID# 283232
Portland, Oregon · Recruiting
Charleston Neuroscience Institute - Charleston /ID# 275047
Charleston, South Carolina · Recruiting
Austin Research Center for Retina /ID# 276101
Austin, Texas · Recruiting
Retina and Vitreous of Texas /ID# 283051
Bellaire, Texas · Recruiting
Star Retina /ID# 276513
Burleson, Texas · Recruiting
Texas Retina Associates - Dallas /ID# 276117
Dallas, Texas · Recruiting
Wagner Macula & Retina Center - Norfolk /ID# 275021
Norfolk, Virginia · Recruiting
Vistar Eye Center - Salem /ID# 282879
Salem, Virginia · Recruiting
Emanuelli Research & Development Center /ID# 275378
Arecibo, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.